Fran DiNuzzo, CEO, added, “We are excited to share our data with potential partners and to discuss the progress in our advanced GAT platform. In addition, we will be showcasing some of our currently available monoclonal antibody collections, such as those around CXCR4 and CD-20 targets, which are currently available for licensing to interested parties. For both targets, we have lead collections of 75 or more molecules. We believe these monoclonal antibody collections may represent differentiated biotherapeutic candidates for biopharma companies.”About SDIX ( www.sdix.com) SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives. In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results. This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “can”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.
SDIX (Nasdaq: SDIX) today announced that it will be showcasing progress with its advanced Genomic Antibody Technology TM (GAT TM) data package this week’s BIO International Convention, one of the largest global partnering events for the biotechnology industry. Advanced GAT is the next generation of the Company’s well-established and successfully marketed proprietary DNA-immunization-based technology. The 2012 event is taking place at the Boston Convention & Exhibition Center in Boston, MA, on June 18-21. SDIX will be participating in the BIO Partnering sessions on June 18-20. Fran DiNuzzo, CEO, and Klaus Lindpaintner, CSO and VP of R&D of SDIX plan to engage in discussions with Biotechnology and Pharmaceutical companies to share new data documenting the capabilities of the advanced GAT platform. Management plans to share recent developments demonstrating the platform’s capabilities to create large collections of novel monoclonal antibodies against transmembrane protein targets, including GPCRs. The company believes that these transmembrane protein targets represent a large potential market opportunity - approximately one third of all currently pursued drug targets. The data will include results from initial targets that include CXCR4 and CD-20. These data show that the company’s proprietary technology created large collections of highly diverse monoclonal antibodies, as indicated by both sequence diversity and epitope mapping data, that are functionally active. “We have recently made substantial progress in creating datasets on large numbers of monoclonal antibodies that demonstrate the strengths of our advanced GAT platform,” commented Dr. Lindpaintner. “Given that creating monoclonal antibodies against GPCRs and other membrane receptors has long been an area of unmet need in the pharma-biotech industry, we believe that these antibody capabilities may offer a large market opportunity for SDIX. Moreover, our platform’s ability to target a broader spectrum of a protein’s epitopes, not just the immunodominant ones, gives us added confidence in advanced GAT’s value proposition.”